Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

93
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
93
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

128
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
128
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

733
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
733
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.4K
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

74
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
74
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

87
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
87

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning Dynamics in Biophysical Spiking Network Models Are Shaped by KCC2/NKCC1 Cotransporter Stoichiometry.

The European journal of neuroscience·2026
Same author

An Artificial Intelligence-Assisted Tool to Predict Continuous Glucose Monitor Adherence in Children with Type 1 Diabetes in Oman: Protocol for a Multi-Phase Mixed Methods Translational Study.

JMIR research protocols·2026
Same author

Worse Function and Symptoms Among the Most Rural Patients With Advanced Cancer: A Cross-Sectional Analysis.

Cancer medicine·2026
Same author

Descending Colon Intussusception Presenting With Bleeding per Rectum.

Cureus·2026
Same author

Research Gaps and Priorities for aHUS in the Gulf Cooperation Countries (GCC): Findings from a Payer-Focused Expert Meeting.

ClinicoEconomics and outcomes research : CEOR·2026
Same author

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure.

Clinical lymphoma, myeloma & leukemia·2026

Related Experiment Video

Updated: Nov 26, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.9K

Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.

Aziza A Ajlan, Roa'a Al-Gain, Mohamed Ahmed

    Journal of the American Pharmacists Association : Japha
    |December 14, 2020
    PubMed
    Summary
    This summary is machine-generated.

    Pharmacists are crucial in managing direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infections. Their involvement optimizes cost-effectiveness and improves patient adherence to treatment protocols.

    More Related Videos

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    18.2K
    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
    23:56

    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

    Published on: October 31, 2010

    17.0K

    Related Experiment Videos

    Last Updated: Nov 26, 2025

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    18.9K
    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    18.2K
    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
    23:56

    Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

    Published on: October 31, 2010

    17.0K

    Area of Science:

    • Hepatology
    • Pharmacoeconomics
    • Infectious Diseases

    Background:

    • Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment outcomes.
    • Cost-effective DAA utilization and patient adherence are critical for successful HCV management.

    Purpose of the Study:

    • To describe the implementation of a multidisciplinary HCV management program at a tertiary care institution.
    • To detail the role of pharmacists in managing DAA therapy, including formulary strategies and monitoring.
    • To outline the development of guidelines and electronic prescribing tools for DAA treatment.

    Main Methods:

    • Established a multidisciplinary HCV taskforce and program clinic.
    • Developed institutional formulary guidelines and patient eligibility criteria for DAAs.
    • Implemented electronic prescribing protocols and conducted medication use evaluations.

    Main Results:

    • Pharmacist involvement enhanced formulary decision-making and reduced therapy costs.
    • Improved adherence to institutional guidelines for DAA treatment was observed.
    • Medication use evaluations monitored treatment response, adherence, and adverse events.

    Conclusions:

    • A multidisciplinary approach is essential for effective HCV treatment with DAAs.
    • Clinical pharmacists are vital in optimizing pharmacotherapy, patient care, and reducing healthcare expenditure in HCV management.